Acetazolamide for central serous retinopathy

Ophthalmology

Volumn 109, Issue 9, 2002, Pages 1723-1725

  Pikkel, Joseph ^a   Beiran, Itzchak ^b   Ophir, Avinoam ^a,c   Miller, Benjamin ^b  

^a HILLEL YAFFE MEDICAL CENTER   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE;

ADULT; ARTICLE; CENTRAL SEROUS RETINOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MALE; NERVOUSNESS; PARESTHESIA; PRIORITY JOURNAL; RECURRENCE RISK; STOMACH DISEASE; TREATMENT OUTCOME; VISUAL ACUITY;

ACETAZOLAMIDE; ADULT; CARBONIC ANHYDRASE INHIBITORS; EXUDATES AND TRANSUDATES; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; RECURRENCE; RETINAL DISEASES; VISUAL ACUITY;

EID: 0036711687     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(02)01157-0     Document Type: Article

References (8)

1. Central serous retinopathy
2. Treatment of chronic macular edema with acetazolamide
3. A direct correlation of the resolution of pseudophakic cystoid macular edema with acetazolamide therapy
4. Inhibition of membrane-bound carbonic anhydrase decreases subretinal pH and volume
5. The role of carbonic anhydrase inhibitors in the management of macular edema
6. Inhibition of membrane-bound carbonic anhydrase enhances subretinal fluid absorption and retinal adhesiveness
7. Inhibition of ocular gamma glutamyl transpeptidase by acetazolamide
8. Central serous chorioretinopathy